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Fibrin glue created from a patient’s own blood can be used as a carrier to deliver cells to the speciﬁc site of an injury. An
experimental model for optimizing various permutations of this delivery system in vivo was tested in this study. Harvested
equine meniscal sections were reapposed with ﬁbrin glue or ﬁbrin glue and equine bone marrow-derived mesenchymal stem
cells (BMSCs). These constructs were then implanted subcutaneously in nude mice. After harvesting of the constructs, BMSC
containing constructs showed signiﬁcantly increased vascularization, and histology showed subjectively decreased thickness of
repair tissue and increased total bonding compared to ﬁbrin alone constructs. This model allowed direct comparison of diﬀerent
meniscal treatment groups while using a small number of animals. This in vivo model could be valuable in the future to optimize
ﬁbrin and cellular treatments for meniscal lesions in the horse and potentially humans as well.
1.Introduction
The meniscus is a C-shaped ﬁbrocartilage structure within
the femorotibial joint [1]. It is integral in providing stability
to the joint [2], lubrication during movement, and absorp-
tion and dissipation of shock [2, 3]. Meniscal injuries can
result from a variety of causes, most notably chronic wear
and tear, acute damage, and cruciate or collateral ligament
laxity [4]. Over time, negative eﬀects of meniscal injury
include joint instability and articular cartilage degeneration.
Medial meniscal injuries comprised 81% of the damaged
menisci reported in humans, and sports activities were the
major cause [5]. Severe meniscal tears in the horse have
resulted in a decreased return to function despite surgical
treatment [6, 7]. Meniscectomy and partial meniscectomy
of severely damaged menisci are not without their long-
term eﬀects on the joint, resulting in osteoarthritis (OA) and
joint disability [8].Treatmentorrepairofthemeniscuswhile
avoidingmeniscectomymayallowthepatienttorecoverwith
decreased long-term dysfunction in the knee or stiﬂe [9, 10].
Eﬀorts to create a synthetic replacement meniscus gen-
erally resulted in suboptimal performance of the implants
with consequential degenerative joint changes in a matter
of weeks to months in test subjects [11, 12] though some
recent progress has been made [13]. Promising options
have arisen using donor menisci as biologic scaﬀolding and
incorporating these into the patient meniscal structure, or
maintaining the patients’ meniscus in situ and encourag-
ing cellular repopulation and vascular in-growth through
various methods [14–20]. Clinicians have begun to implant
stem cells or platelet rich plasma into visible lesions via
ultrasonography or arthroscopy. Fibrin glue derived from
the patient’s own blood can be used as a carrier to adhere
the cells in the damaged region [17, 21]. A study in rabbits
by Ishimura et al. [22] placed ﬁbrin glue and whole bone
marrow aspirate into defects in the avascular zone of the
meniscus. This resulted in drastically more mature healing
within 12 weeks than ﬁbrin alone or empty defects. One
version of this cellular/ﬁbrin treatment has been pioneered
by Scotti et al. [20] using chondrocytes implanted in ﬁbrin
glue to reappose cadaver meniscal sections. Their study
showed increased bonding of the sections in the chondrocyte
samples versus ﬁbrin glue alone.
The aforementioned studies suggest the possibility that
implantingviablecellsinﬁbringluedirectlyintoalesionmay
give rise to new advances in cell-based meniscal healing. Our2 Stem Cells International
laboratory has used intra-articular injection of autogenous
bone marrow-derived mesenchymal stem cells (BMSCs)
in the treatment of meniscal lesions in the horse for the
last 4 years [23, 24] and has seen encouraging results for
horses with severe meniscal lesions. Intra-articular injection
of adult stem cells from bone marrow expansion showed
signiﬁcant regeneration of meniscal tissue in a caprine
experimental model and a human clinical case [25, 26].
Intra-articular injection of BMSCs is not injury site speciﬁc,
relying on inﬂammatory homing mechanisms [21, 27, 28]
for the cells to migrate to the damaged tissues. The current
project was developed to further examine the eﬀects of
more directed site-speciﬁc cellular treatment using ﬁbrin as
a carrier. Utilizing the murine model published by Scotti et
al. [20]o ﬀers a variety of beneﬁts that make it a suitable
step between in vitro and larger scale in vivo work. The
model provides the ability to experiment with meniscal
constructs of a controlled size, type, and treatment in
suﬃcient numbers with cohort controls to provide adequate
statistical power. Such a model allows testing of various
treatment permutations in a relatively short amount of time.
These include dose (cell numbers), type or concentration of
ﬁbrin, degree of diﬀerentiation in multipotent cell lines, and
addition of growth factors or other biologic substances in a
controlled in vivo setting. The result will enable researchers
to determine the optimal treatment strategies utilizing these
modalities in larger animal models. The purpose of the
current study was to determine if beneﬁcial healing eﬀects
from implantation of BMSCs in ﬁbrin could be observed
compared to ﬁbrin alone.
2.MaterialsandMethods
All procedures involving live animals and collection of tissue
forthisstudywereapprovedbytheColoradoStateUniversity
Animal Care and Use Committee.
2.1. Meniscal Tissue Collection. Eight medial menisci were
collected from four horses euthanized for reasons unrelated
to the stiﬂe joint or other factors that would adversely aﬀect
the study. Menisci were harvested in an aseptic manner from
cadaver limbs within 6 hours following euthanasia (with a
range of 30 minutes to 6 hours), held in phosphate buﬀered
saline (PBS) (Invitrogen Corporation (Headquarters) Carls-
bad, CA, USA), snap frozen in liquid nitrogen, and then
stored at −80◦C for a minimum of 1 week (with a range
from 1 week to 8 months). Samples were thawed in a 25◦C
water bath, trimmed to retain only the axial 2/3 of the
meniscus, and sectioned further into 0.4cm wide triangular
wedges. Sections were placed into PBS and PSA (penicillin,
streptomycin, and amphotericin B) (Invitrogen Corporation
(Headquarters) Carlsbad, CA, USA) and passed through two
additional freeze-thaw cycles [29], changing the media to
freshPBS(InvitrogenCorporation(Headquarters)Carlsbad,
CA, USA) with each freeze-thaw cycle, to ensure that no
viable cells were present.
2.2. Bone Marrow. Bone marrow was collected from the
ilium of a horse euthanized at CSUVTH (Colorado State
University Veterinary Teaching Hospital) for unrelated rea-
sons within 30 minutes of euthanasia with an 8-gauge
Jamshidi trocar using sterile technique. Approximately 20cc
bone marrow was drawn into 2–35cc syringes with 3,000
units of heparin (APP Pharmaceuticals LLC, Schaumbeurg,
IL, USA) anti-coagulant in each syringe. Bone marrow mes-
enchymal stem cell colonies were obtained by culturing the
nucleated cell fraction according to the technique described
by Kisiday et al. [30]. After reaching 60–70% conﬂuence,
each culture was passaged by lifting the BMSCs with
trypsin (Invitrogen Corporation (Headquarters) Carlsbad,
CA, USA), reseeding at 10,000cells/cm2, and allowing the
BMSCs to grow to 60–70% conﬂuence. The BMSCs were
cryopreserved in 95% autogenous serum/5% DMSO (Sigma
Aldrich, St. Louis, MO, USA).
2.3. Fibrin. Four hundred milliliters of equine venous blood
was collected in a sterile manner from the jugular vein of a
donor into a blood collection set (Jorgensen Laboratories)
with sodium citrate anti-coagulant and stored at 4◦Cf o r
several hours. Whole blood was centrifuged at 1000G for
10 minutes and the plasma removed and stored at −80◦C
until needed. Plasma was thawed at room temperature, and
the ﬁbrin extracted per the ethanol precipitation protocol
described by Yoshida et al. [31].
2.4. Construct Preparation. Preprepared meniscal sections,
BMSCs, and ﬁbrin were thawed immediately prior to con-
structcreation.Constructpairsforeachmouse(Group0and
Group 1) were created from sections of the same meniscus
to control for variation. For Group 1 constructs, thawed cell
suspension was pelleted, then resuspended with the minimal
amount of ﬁbrinogen free plasma (approximately 50µL)
needed to return cells to suspension. The cell suspension was
thenmixedwith225µLﬁbrinogenprecipitateandadditional
ﬁbrinogen-free plasma (approximately 175µL) until a ﬁnal
cell concentration of 10 × 106 cells per mL of ﬁbrinogen/
plasma/cell mixture was reached. Equal parts (0.02mL) of
theﬁbrinogen/plasma/cellmixtureweremixedwithanequal
amount of bovine thrombin (MP Biomedicals, Santa Ana,
CA,USA)(0.02mL)andappliedtothecutsurfacesofGroup
1 meniscal sections. A second meniscal section was placed
on top of the ﬁbrinogen/plasma/cell mixture and the ﬁbrin
a l l o w e dt os e tf o r3 0m i n u t e s .
Group 0 samples were created using 50µL of PBS to
replace the BMSC/plasma suspension. This was then mixed
with 225µL ﬁbrinogen precipitate and 175µL of ﬁbrino-
gen free plasma. Equal parts (0.02mL) of the ﬁbrino-
gen/PBS/plasma mixture were mixed with bovine thrombin
(MP Biomedicals, Santa Ana, CA, USA) (0.02mL) and
applied to the cut surfaces of Group 0 meniscal sections.
A second meniscal section was placed on top of the ﬁb-
rin/PBS/thrombin mixture and the ﬁbrin allowed to set for
30 minutes. To coat the exterior of all constructs, ﬁbrinogen
precipitate (225µL) was mixed with ﬁbrinogen free plasma
(225µL) and mixed with equal volumes of thrombin. This
coating was applied to decrease subcutaneous tissue invasion
in vivo [20]. Approximately 0.1mL of ﬁbrin and thrombinStem Cells International 3
mixture was used to completely coat each construct. The
exterior ﬁbrin coating was allowed to set for 30 minutes
before the completed constructs were transferred to a
sterile dish for transport to the surgical suite. Constructs
were assembled and completed in groups of 6 of each
treatment group between 15 minutes and 45 minutes prior
to implantation.
2.5. Surgical Procedure. Twelve 10-week-old male nude mice
were anesthetized, maintained on isoﬂurane inhalant anes-
thesia, and administered 5mg/kg carprofen (Pﬁzer Animal
Health, Madison, NJ, USA) subcutaneously. Mice were
placed in sternal recumbency and bilateral paralumbar areas
werepreppedwith2%Chlorhexidinescrubandsterilewater.
Surgical procedure was modeled after previously described
protocols [20, 32]. A 1cm horizontal cutaneous incision
was made in each paralumbar area and a pocket bluntly
dissected into the subcutaneous tissue. A meniscal construct
was inserted into each pocket, one side randomly receiving a
BMSC and ﬁbrin-treated sample and a ﬁbrin only control
sample in the other [32]. The incisions were closed with
wound closure clips (AUTOCLIP) (Becton, Dickson and
Co. Franklin Lakes, NJ, USA). Ear notches were used to
uniquely identify each mouse. Mice were recovered and were
monitored twice daily for three days following surgery. Mice
received 5mg/kg of Carprofen subcutaneously for 3 days
followingsurgery.Afterthreedays,theyweremonitoredonce
daily for the remaining 4 weeks of the study for signs of
postoperative complications and general well-being.
2.6. Harvesting of Constructs. At 4 weeks after surgery, mice
were placed in a CO2 gas chamber and humanely euthanized
with a gradually increasing concentration of CO2 (starting
with room air) until the mice ceased to breathe. A lack of
heart beat was conﬁrmed before the mice were completely
removed from the chamber. The constructs were removed,
immediately ﬁxed in 10% neutral buﬀered formalin (StatLab
Medical ProductsMcKinney, TX, USA), and graded for
presence of tissue adhesion, adherent vessels, and perceived
strength of bond between the sections when bluntly probed.
Twenty four meniscal samples in total were harvested from
12 animals, with a Group 1 and Group 0 harvested from
each animal as modeled by Peretti et al. (2001) [32]. Grading
scores and criteria are illustrated in the rubric in Table 1.
2.7. Scoring. Am o d i ﬁ e dR o d e oe ta l .[ 33] scoring system
was used. See Table 1 for the complete rubric. The outcome
parameter “Adherent vessels” graded on a scale of 0–2 the
extent of subcutaneous vascular adherence to each surface
of the construct. The outcome parameter “Tissue adhesion”
(scale 0–1) graded adherence of mouse subcutaneous tissue
to the surface of the construct. The outcome parameter
“Bond” scored the apparent adhesion between the two
sections when gently probed along the junction of the two
sections (0–2). A classiﬁcation of “No bond” was determined
if the two sections separated completely with gentle probing,
“ﬂexible bond” was determined as one that maintained
apposition but the sections could be slightly shifted in
relationship to each other, and a “ﬁrm” attachment was one
where no movement was noted between the sections when
probed.
2.8. Histology. Five micron sections were created from
paraﬃn-embedded constructs in a plane perpendicular to
the bonded edge. Two random tissue sections from the
central area of each sample were selected and placed into two
diﬀerent staining groups. Tissues were applied to slides and
stained with haematoxylin and eosin (H&E); (Anatech LTD;
Battle Creek, MI, USA) and Safranin O-Fast Green (SOFG) (
Electron Microscopy Sciences, Hatﬁeld, PA, USA) stain and
examined microscopically.
The outcome parameter “cellular ingrowth” graded the
cellular inﬁltrate along the repair tissue interface to repopu-
late the acellular meniscal tissue (0–3). The outcome param-
eter “predominant cell type” assessed the population of
cells present in the repair tissue and their relative frequency
(1–3). The outcome parameter “ﬁber organization” graded
the repair tissue as organized or disorganized (0–2 scale).
The outcome parameter “ﬁbrinous tissue between sections”
graded the amount of ﬁbrinous tissue noted between the
meniscal sections at the time of analysis (0–1). This tissue
was assumed to be remnants of the ﬁbrin glue which was
placed between the sections during construct creation. The
outcome parameter “SOFG % positive staining” assessed the
amount of the repair tissue that exhibited SOFG positive
staining (0–3). The outcome parameter “thickness of repair
tissue” assessed the thickness of the repair tissue that was
present between the meniscal sections (0–2). The outcome
parameter “cell repopulation” analyzed the presence of cells
throughout the body of the meniscal section (0–2).
The outcome parameter “total percent bonded” was
completed on a microscope at 20x–40x power and measured
on digital capture images of the slide sections (Adobe
Photoshop CS Extended Edition 10.0.1) Additional images
for publication were obtained (Leica DFC 425 camera, LAS
Core software, Buﬀalo Grove IL, USA). Slide images of the
sections were measured for a total length of the repair area
(area of interface between the cut sections). Images were
then marked where evidences of bonding (bridging and
incorporation of meniscal ﬁbers into the repair tissue) were
noted along the length of the repair. Bonded measurements
were recorded and converted to a percentage of the total
repair section. These total percentages were grouped into 4
groups and assigned a score of 0–3 based on Table 1.
2.9. Statistical Analysis. F i s h e r sE x a c tT e s ta n dC h i - S q u a r e
table analysis were performed on all data (SAS v.9.2., SAS
InstituteIncorporated,Cary,NC).Statisticalsigniﬁcancewas
set at P ≤ 0.05 and a statistical trend was deﬁned as P ≤ 0.1.
3. Results
There were no morbidities or mortalities in any of the
study animals. At a 3 day post operative examination it was
noted visually through the skin of two mice that two of the
constructs had shifted so that sections were no longer in
apposition on the cut surfaces (one was sitting edge to edge,
one was sitting edge to cut surface). Both samples were in4 Stem Cells International
Table 1: Explanation of grading rubric used in the current study and the coding used for the results.
C a t e g o r y / s c o r e 01 23
Gross observations
Adherent vessels Vessels on 1 side only Vessels on 2 sides Multiple vessels on
multiple sides
Tissue adhesion No Tissue Adhesion Areas of external
tissue adhered
Bond No bond Flexible bond Firm attachment
H&E section observations
Cellular in-growth Acellular along cut edge
Incomplete
cellular
repopulation
50% in-growth
Complete
repopulation
along cut edge
Predominant cell type Small round cells
(ﬁbrocytes)
Larger less dense cells
(inﬂammatory origin)
50-50 dispersed
Fiber organization Disorganized 50% parallel
ﬁbers
Greater than 70%
organization
Fibrinous tissue between sections Large amounts of
ﬁbrous tissue present
No large ﬁbrous
tissue sections
present
SOFG section observations
SOFG % positive staining None Less than 50% More than 50% Near 100%
Thickness of repair tissue Thin Medium Thick
Cell repopulation Rare Moderate Frequent
Total bond distance 25% 25–50% 50–75% 75–100%
the cell-treated group (Group 1). Once cut in for histology,
these samples had bonding evidenced between the sections
and were graded along with the rest of the samples. For
complete results of the scoring rubric for each sample, see
Table 2.
3.1. Gross Observations. All constructs had ﬁbrinous coating
remaining, noted upon removal from the mouse. There
was a statistically signiﬁcant diﬀerence (P = 0.0094) in
the presence of “Adherent vessels” to the construct surfaces.
Group 0 had four (4/12, 33.3%) constructs with vessels
present only on one side while Group 1 constructs all had
vessels present on two sides (10/12, 83.3%) and multiple
sides (2/12, 16.7%). Please see Table 2 for complete scoring
results. See Figure 1(a) f o ra ni m a g eo faG r o u p1c o n s t r u c t
with multiple vessels adherent to the surface and Figure 1(b)
for a Group 0 construct with minimal vessels present only on
one surface. There was no statistical diﬀerence (P = 1.0) in
external “tissue adhesion” between treatment groups. Group
1 constructs had no presence of tissue adhesion in 5/12
(41.7%) and did have presence of tissue adhesion in 7/12
constructs (58.3%). Group 0 also had 5/12 constructs with
no evidence of external tissue adhesion and 7/12 constructs
with presence of tissue adhesion. There was no signiﬁcant
statistical diﬀerence (P = 0.64) in the level of subjective
of “Bond” between treatment groups. While some sections
had a ﬂexible bond, it was noted that all sections were
adhered together and more resistant to separation with
pressure applied at the cut edge than they had been prior
to implantation, indicating the occurrence of bonding in all
constructs. Please see Table 2 for a breakdown of the full
results of these outcome parameters.
3.2. H&E-Stained Sections. There was no statistical signif-
icance (P = 1.0) in “cellular ingrowth” from the repair
tissue into the meniscal sections between treatment groups.
There was no statistically signiﬁcant diﬀerence (P = 0.822)
in the “predominant cell type” present in the repair tissue
between the treatment groups. Some sections had very
organized repair tissue with parallel ﬁbers; however, these
parallel ﬁbers were mostly oriented perpendicular to the
meniscal ﬁbers. While there subjectively appeared to be a
relationship between treatment group and ﬁber organiza-
tion, this was not statistically signiﬁcant (P = 1.0). There
was no statistical diﬀerence (P = 0.214) in the amount
of ﬁbrinous tissue remaining in the repair area between
sections when comparing the treatment groups. Subjectively,
larger amounts of ﬁbrinous tissue were present in non-
cell-treated sections than in cell-treated sections with 7/12
(58.3%) of the Group 0 constructs having a large amount
of ﬁbrinous tissue present compared to only 3/12 (25%)
in the Group 1 constructs. Figure 2(a) shows a histologic
section from Group 1 illustrating the absent ﬁbrinous tissue
and showing vascular ingrowth into the repair tissue and
progressing between the cut sections. Figure 2(b) shows a
histologic section from Group 0 showing thick ﬁbrinous
tissue present. There is still some vessel ingrowth present
in the ﬁbrinous tissue. There was no statistical diﬀerence
in the “total bond distance” between treatment groups
(P = 0.569). However, Group 1 (Figure 3(a))s u b j e c t i v e l y
showed better bonding overall with 11/12 (91.7%) sectionsStem Cells International 5
Table 2: Group 0 is ﬁbrin only treatment; Group 1 is ﬁbrin with BMSCs treatment. See Table 1 for grading score rubric.
Category/Score Group 0 1 2 3 P value
Gross observations
Adherent vessels Group 0 4 (33.3%) 3 (25%) 5(41.7%) 0.0094
Group 1 0 (0%) 10 (83.3%) 2 (16.7%)
Tissue adhesion Group 0 5 (41.7%) 7 (58.3%) 1.00
Group 1 5 (41.7%) 7 (58.3%)
Bond Group 0 2 (16.7%) 10 (83.3%) 0.640
Group 1 4 (33.3%) 8(66.7%)
H&E section observations
Cellular in-growth Group 0 3(25.0%) 6 (50.0%) 3(25.0%) 1.000
Group 1 3(25.0%) 5 (41.7%) 4 (33.3%)
Predominant cell type Group 0 8 (66.7%) 1(8.3%) 3(25.0%) 0.822
Group 1 6(50.0%) 1(8.3%) 5(41.7%)
Fiber organization Group 0 3(25.0%) 7(58.3%) 2(16.7%) 1.000
Group 1 2(16.7%) 7 (58.3%) 3(25.0%)
Fibrinous tissue between sections Group 0 7(58.3%) 5(41.7%) 0.214
Group 1 3(25.0%) 9(75.0%)
Total bond distance Group 0 0 3(25.0%) 4(33.3%) 5(41.7%) 0.569
Group 1 0 1(8.35) 7(58.3%) 4(33.3%)
SOFG section observations
SOFG % positive staining Group 0 5(41.7%) 3(25.0%) 4(33.3%) 0 0.428
Group 1 5(41.7%) 5(41.7%) 1(8.3%) 1(8.3%)
Thickness of repair tissue Group 0 5(41.7%) 6(50.0%) 1(8.3%) 0.680
Group 1 8(66.7%) 3(25.0%) 1(8.3%)
Cell repopulation Group 0 5(41.7%) 6(50.0%) 1(8.3%) 0.520
Group 1 7(58.3%) 3(25.0%) 2(16.7%)
(a) (b)
Figure 1: (a) Multiple vessels externally adhered to Group 1 meniscal construct. The vessels can be seen entering the cut area between the
two sections. (b) Group 0 construct with minimal evidence of vessels on only one surface.6 Stem Cells International
100 µm
(a)
100 µm
(b)
Figure 2: (a) shows thin repair tissue and vasculature ingrowth in Group 1 meniscal section. (b) shows a grouping of small vessels within a
large amount of ﬁbrinous tissue between two meniscal sections in Group 0 construct.
100 µm
(a)
100 µm
(b)
Figure 3: (a) A cell-treated (Group 1) meniscal section with cellular repopulation of the acellular meniscal tissue and evidence of bridging
between the two meniscal sections, especially in the upper aspect of the image. (b) A non-cell-treated section (Group 0) with separation of
the repair tissue from the meniscal ﬁbers on the right-hand side (indicative of a less robust attachment). While this detachment occurred
during processing, a lack of bonding can be seen on the left side of the repair tissue as well.
exhibiting bonding characteristics evident in greater than
50% of the repair area compared to 9/12 (75.0%) of Group
0( Figure 3(b)) constructs with bonding characteristics over
50% or more of the repair area.
3.3. SOFG-Stained Sections. Figures 4(a) and 4(b) show two
examples of SOFG-stained sections. There was no signiﬁcant
diﬀerence in “SOFG % positive staining” between groups
(P = 0.428) with Group 0 exhibiting the same number of
constructs with negative SOFG (i.e., green counter staining)
(5/12, 41.7%) compared to Group 1 (5/12, 41.7%). While
Group 0 had more constructs (4/12, 33.3%) that exhibited
50% or more positive SOFG staining compared to Group
1 (2/12, 16.6%), this diﬀerence was not signiﬁcant. When
examining “thickness of repair tissue” present and treat-
ment group, there was no statistically signiﬁcant diﬀerence
between groups (P = 0.680). Based on subjective scoring,
there appeared to be less repair tissue present between
the sections in Group 1 (8/12 (66.7%) with thin repair
tissue) compared to Group 0 (5/12 (41.7%) with thin repair
tissue). Finally, there was no statistical diﬀerence noted
when examining “cellular repopulation” in the body of
the meniscal sections (away from the cut edge) between
treatment groups (P = 0.520).
4. Discussion
This study allowed comparison of repair and bonding
diﬀerences of acellular meniscal sections when treated with
BMSCs and ﬁbrin compared to ﬁbrin alone in a controlled
in vivo model. Overall, results showed signiﬁcantly increased
vascularadherencetoBMSCandﬁbrin-treatedsections(P =
0.0094). Subjectively the results showed improved character-
istics of increased bonding and healing in constructs treated
with stem cells and ﬁbrin compared to constructs with ﬁbrin
only in the outcome parameters of “ﬁbrinous tissue between
sections”,“thicknessofrepairtissue”,and“total%bonded”.It
is to be noted that the statistical results of this study are likely
limited by subtle diﬀerences between the treatment groups
and small sample size.
The degree of bonding seen in constructs treated with
ﬁbrin only in the current study appeared diﬀerent when
compared with previously published work. Speciﬁcally,
Scottietal.[20]sawnoevidenceofbondingbetweensections
in their ﬁbrin only group and did not report evidence ofStem Cells International 7
200 µm
(a)
200 µm
(b)
Figure 4: (a) and (b) show SOFG-stained sections with little positive SOFG-stain uptake. There was no signiﬁcant diﬀerences between the
SOFG staining between groups. Cellular repopulation along the cut edge is evident in both sections.
vascular inﬁltration in any of the experimental constructs in
their study. In contrast, the current study showed multiple
signs of bonding within the ﬁbrin only treatment group as
well as the BMSC-added group. There were vessels present
between the sections in both treatment groups in the current
study. It is unclear what resulted in this discrepancy between
the results of the two studies. Potentially it could have been
due to the diﬀerence in the ﬁbrin sources. Scotti et al.
[20] used a commercially prepared porcine ﬁbrin product
whereas the current study utilized equine ﬁbrin drawn
and prepared on-site, as would be commonly performed
in a clinical setting. Another potential diﬀerence between
the studies was the thickness of the ﬁbrin coating. Images
published by Scotti et al. [20] showed thicker layers of
ﬁbrin surrounding the constructs than was achieved in the
current study. A thicker layer of ﬁbrin would potentially
limit vascular invasion and alter the diﬀusion and delivery
of exogenous oxygen, cytokines, and cells to the construct.
In humans, while the outer third of the meniscus is
well vascularized due to connections to the joint capsule,
the axial portion is essentially avascular [34, 35]. Due to
this diﬀerence, the outer portion of the meniscus is more
likely to heal with a viable repair [34, 35]. The thinner
avascular portion and meniscal ligament attachments are
more likely to have a suboptimal repair and more likely to
become reinjured on return to strenuous activity [14, 34].
Treatment of the constructs with BMSCs appeared to result
in a greater and more consistent revascularization of the
constructtissues.Thereweresigniﬁcantly(P = 0.0094)more
vessels externally adhered to Group 1 constructs compared
to Group 0 constructs in the current study. For an example,
please see Figures 1(a) and 1(b). It is possible that vascular
growth factors released by the BMSCs [21, 36, 37]r e s u l t e di n
a stimulus for vessel in-growth in the cell-treated sections,
and these growth factors were not present in the previous
study by Scotti et al. [20] which utilized chondrocytes in
their cell constructs. It is also plausible that these growth
factors may have also aﬀected the non-BMSC (Group 0)
sections implanted in the same mouse. Having both Group 0
and Group 1 constructs in the same mouse would allow
growth factors to be systemically absorbed or to spread
locally through the subcutaneous space. This may have
accounted for the increased vascularity seen in the current
study compared to Scotti et al. [20]. Increased vascular
formation is often a goal of meniscal healing treatments in
order to provide physiologic support for repair tissues in the
meniscus. Thus the increased vascularity seen here could be
a beneﬁt in clinical use [38, 39].
Scotti at al. [20] reported more linear ﬁbrous repair
tissue and less ﬁbrin remnant in the chondrocyte-treated
constructs. These results are mirrored in the results of the
current study with the BMSC-treated constructs: thinner
repair tissue (66.6% of Group 1 compared to 41.75% of
Group 0 constructs with thin repair tissue) and less ﬁbrinous
remnants (25% of Group 1 constructs had large amounts of
ﬁbrinous material between section compared to 58.3% in
Group 0). One explanation for this result is that the cell-
treated samples created a repair tissue with less extraneous
scar tissue than those without cells.
Mature meniscus contains live ﬁbrochondrocytes despite
the avascular nature of the axial portion. If an injury
occurs and viable cells are still present, these cells can be
recruited for healing. However, studies have shown that
ﬁbrochondrocyte apoptosis is closely related to, and may
evenprecede,meniscaldamage[40].Apoptosisthatoccursin
an injured area greatly reduces the ﬁbrochondrocytes avail-
able for repair, and lack of vascularity limits the opportunity
for cells to migrate in from other locations [41]. In a large
retrospectivestudyofhumanswithinjuredmenisci,Englund
et al. [10] found that degenerative meniscal damage was less
likely to have a satisfactory return to function compared to
traumatically injured menisci. Most of the constructs in both
Group 0 (9/12) and Group 1 (9/12) in the current study
had cellular ingrowth from the cut edge and repair tissue
present. These cells could contribute to repopulation of the
avascular meniscal section and ultimately increase healing.
This repopulation of the acellular meniscal tissue would also
be critical in healing as presence of ﬁbrochondrocytes would
be necessary for long-term viability of the meniscal implant.
It was beyond the scope of this study to determine the origin
of the repopulated cells.8 Stem Cells International
The study presented here aided in further describing
this model and resulted in signiﬁcant results that may
have clinical implications. Utilizing this model could allow
further investigations to better deﬁne optimal conditions for
ﬁbrin and BMSC treatment in live animals. Unpublished
studies in vitro in our laboratory have suggested that speciﬁc
concentrations of ﬁbrin may be optimal for migration of
BMSCs; however, these more dilute concentrations may not
oﬀer as much support to maintain tissue apposition during
the early healing phases. Using this model and cellular
markers [38, 42] to track migration of cells at diﬀerent
time points may help to determine the most physiologically
eﬀective concentration of ﬁbrin to utilize in vivo.I d e a l
dosage of cells per surface area treated may be investigated as
well. Further studies with cell marking techniques will also
provide information on the source of cells participating in
the repair tissue between the sections and aid in determining
what cells are repopulating the meniscal tissue. This may
enable medical personnel to better target treatment to
increase positive outcomes in diﬃcult meniscal injuries.
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